Posts Tagged ‘New York Times’

Ok, New York Times, you had me at hello. The Old Gray Lady’s coverage of the secret corporate funding of political campaigns has been encouraging. This week, Mike McIntire looked at some of the shady dealings of astroturf groups:

An examination of Americans for Job Security — based on a review of its recent activities, as well as on interviews and previously unreleased documents from the Alaska case — provides a rare look inside the opaque world of these ascendant advocacy organizations. Its deep ties to a Republican consulting operation raise questions about whether, under cover of its tax-exempt mission “to promote a strong, job-creating economy,” the group is largely a funnel for anonymous donations.

McIntire quotes Taylor Lincoln, research director of Public Citizen’s Congress Watch division: “A lot of nonprofits game the system, but A.J.S. is unusual in that they so blatantly try to influence elections and evade disclosure. By any common-sense, reasonable interpretation of what they do, they are in violation of the rules.”

Taylor helped put together the report we issued this month that noted that more than two-thirds of the (more…)

Read Full Post »

A daily look at news from the Washington Post, New York Times and Wall Street Journal that caught our eye:

BP Oil Spill
  • Behind scenes of oil spill, acrimony and stress (NYT)
  • BP official questioned about who had final responsibility in drilling work (WP)
  • Spill Damage Claims Absent the Spill (WSJ)
  • Hip implants are recalled by J&J unit (NYT)
  • The wrong prescription for Medicare (WP)
  • States press workers on health care (WSJ)
  • J&J’s Latest Recall: Hip-Repair Implants (WSJ)
  • Economic growth slowed by trade gap (WP)
Climate, Energy
  • Administration backs utilities in climate case (WP)
  • A Shaky Advance Led by Oil Money (WSJ)
Financial Reform
  • Credit reforms reach campuses (WP)
Social Justice
  • Nod to national security concerns advances bill to protect whistleblowers (WP)

Read Full Post »

A daily look at news from the Washington Post, New York Times and Wall Street Journal that caught our eye:

  • Despite reform, banks have room for risky deals (NYT)
  • Missing piece in oil rig inquiry: Who was in charge? (NYT)
  • Wal-Mart asks Supreme Court to hear discrimination suit (NYT)
  • Lawyers take over at spill inquiry (WP)
  • Scrambled deregulation (WP op-ed)
  • On Doomed Rig’s Last Day, A Divisive Change of Plan (WSJ)
  • Health-Insurance Market Moves Ahead in California (WSJ)
  • BP Casts Blame on Failure of Device (WSJ)
  • The Gulf Claims Racket (WSJ opinion)
  • Coal Gets Burned by Low Gas Price (WSJ)
  • Study Restores Damaged Corneas (WSJ)

Read Full Post »

Tomorrow, our own Sid Wolfe will be testifying before an FDA advisory committee about the much talked about diabetes drug Avandia, manufactured by drug maker GlaxoSmithKline.  The New York Times reported today that GlaxoSmithKline hid data indicating Avandia’s adverse effects for 11 years. The New York Times also explained the history of this dangerous drug.

In the fall of 1999, the drug giant SmithKline Beecham secretly began a study to find out if its diabetes medicine, Avandia, was safer for the heart than a competing pill, Actos, made by Takeda.

Avandia’s success was crucial to SmithKline, whose labs were otherwise all but barren of new products. But the study’s results, completed that same year, were disastrous. Not only was Avandia no better than Actos, but the study also provided clear signs that it was riskier to the heart.

But instead of publishing the results, the company spent the next 11 years trying to cover them up, according to documents recently obtained by The New York Times. The company did not post the results on its Web site or submit them to federal drug regulators, as is required in most cases by law.

Excuse our impatience, but we’ve been warning about Avandia for a decade. We petitioned the Food and Drug Administration to ban Avandia (also known as Rosiglitazone) back in 2000. Sid Wolfe has been saying all the things “recently uncovered” for years. It finally looks like something might happen though; the FDA is meeting to discuss Avandia today.

Check out Public Citizen’s history advocating for the removal of Avandia from store shelves.

You should also look at worstpills.org, our comprehensive fact-check website for all sorts of medications.

Read Full Post »